Literature DB >> 14566155

Nocturnal oximetry: utility in the respiratory management of amyotrophic lateral sclerosis.

Lauren B Elman1, Andrew D Siderowf, Leo F McCluskey.   

Abstract

OBJECTIVE: Current recommendations are to institute nocturnal nasal ventilation for amyotrophic lateral sclerosis patients with a forced vital capacity (FVC) of <50% of predicted normal. The purpose of this study was to determine whether this is appropriate.
DESIGN: A total of 87 nocturnal oximetry evaluations were performed on 78 consecutive amyotrophic lateral sclerosis patients symptomatic for sleep-disordered breathing. Nocturnal oximetry measurements were compared for those with FVC >50% vs. those with FVC of <50% of normal. FVC was measured sitting and supine.
RESULTS: A considerable number of these symptomatic patients manifested evidence of nocturnal hypoxemia as measured by oximetry. However, there was no significant difference between patients with sitting percentage-predicted FVC above and below 50% predicted in minimum oxygen saturation, mean oxygen saturation, percentage of time spent with oxygen saturation of <88%, and number of events per hour. There was no significant difference between patients with supine percentage-predicted FVC above and below 50% predicted in minimum oxygen saturation, mean oxygen saturation, percentage of time spent with oxygen saturation of <88%, and number of events per hour.
CONCLUSION: The recommendation that FVC be <50% of normal is inappropriate for justifying introduction of nocturnal nasal ventilation. Many patients are symptomatic at higher FVC and manifest evidence of nocturnal hypoxemia. Nocturnal oximetry adds additional practical information for justifying earlier respiratory intervention for symptomatic patients.

Entities:  

Mesh:

Year:  2003        PMID: 14566155     DOI: 10.1097/01.PHM.0000091985.22659.30

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  2 in total

Review 1.  Neuromuscular disorders and sleep.

Authors:  Ibrahim Oztura; Christian Guilleminault
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 2.  Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R G Miller; C E Jackson; E J Kasarskis; J D England; D Forshew; W Johnston; S Kalra; J S Katz; H Mitsumoto; J Rosenfeld; C Shoesmith; M J Strong; S C Woolley
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.